Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Mavrilimumab

Home DrugsMavrilimumab

Investigational

Biotech

Mavrilimumab

Unknown Manufacturer

Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Overview

Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.

Technical identifiers

CAS Number: 1085337-57-0
UNII ID: 1158JD1P9A

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Treatment For Rheumatoid Arthritis
- US 2014335081 A1
  Applicant: MEDIMMUNE LTDPriority: 2012
  CN
  US
  2 publications
- CN 106456761 A
  Applicant: MEDIMMUNE LTDPriority: 2014
  CN